Rebirthel concluded the research collaboration agreement with Fujita Health University. – Joint development of the therapy for the novel coronavirus infection using universal killer T cells –

NEWS 2020.10.14 Rebirthel concluded the research collaboration agreement with Fujita Health University. – Joint development of the therapy for the novel coronavirus infection using universal killer T cells –

Rebirthel Co., Ltd. concluded an agreement to collaborate with Fujita Health University to develop a new therapy for novel coronavirus infection and entered into the contract. Killer T cells which are regenerated from iPS cells will be used. For details, please refer to the attached press release.

Click>> 20201014_Rebirthel_Fujita-Health-University_Press-release ダウンロード